Editas Medicine (EDIT) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed Editas Medicine (EDIT) over the past year, gaining 52.3% versus a loss of 30.0%. Over five years, TECX leads with a -67.4% price change compared with -92.8% for EDIT. Tectonic Therapeutic is the larger company by market cap ($444.0 million vs $422.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | TECX |
|---|---|---|
| Share price | $2.75 | $22.71 |
| Market cap | $422.35M | $443.97M |
| 1-day change | +0.73% | +1.34% |
| YTD return | +34.15% | +8.87% |
| 1-year return | -30.03% | +52.31% |
| 5-year return | -92.77% | -67.37% |
| EPS (TTM) | $-0.68 | $-4.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $39.53 |
| 52-week low | $1.66 | $15.32 |
| Distance from 52-week high | -36.49% | -42.55% |
| Average volume | 2.48M | 219.12K |
| Shares outstanding | 153.58M | 19.55M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed EDIT by 82.3 percentage points over the past year.
EDIT vs TECX FAQ
Which is bigger, Editas Medicine or Tectonic Therapeutic?
Tectonic Therapeutic (TECX) is larger, with a market capitalization of $443.97M compared with $422.35M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or TECX?
TECX returned +52.31% over the past 12 months, compared with -30.03% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.